Sergei V. Cheremushkin

Sergei V. Cheremushkin

Auto-generated profile, based on publicly available information

Sergei V. Cheremushkin

Russian University of Medicine

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2025 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
IMIgor V. Maev
Igor V. Maev
DADmitrii Nikolaevich Andreev
Dmitrii Nikolaevich Andreev
AFAlexey Fomenko
Alexey Fomenko
MPM S Podporin
M S Podporin
SLSvetlana Lyamina
Svetlana Lyamina
OZO V Zayratyants
O V Zayratyants
Aim. To determine the trends of primary antibiotic resistance of Helicobacter pylori strains isolated from patients living in Moscow. Materials and methods. As part of a clinical and laboratory study, 123 gastric biopsy specimens from H. pylori-infected patients were analyzed from 2015 to 2024. H. pylori infection was verified by a rapid urease test and a 13C-urease breath test. The anaerobic culture technique was used. After identifying a pure culture, its susceptibility to four antibacterial agents (amoxicillin – AMC, clarithromycin – CLR, metronidazole – MET, tetracycline – TET) was determined by the disc diffusion method. Results. According to the data, the resistance in the overall pool (n=123) of the test samples to AMC was 4.88%, CLR 16.26%, TET 3.25%, and MET 46.34%. Dual resistance to CLR and MET was detected in 4.06% of strains. Among strains collected from 2015 to 2019 (n=28), resistance to AMC was 0.0%, CLR 10.71%, TET 0.0%, and MET 50.0%. The structure of antibiotic resistance of strains collected from 2020 to 2024 (n=95) was as follows: AMC – 6.32%, CLR – 17.89%, TET – 4.21%, MET – 45.26%. Conclusion. There is a gradual tendency to increase the resistance of H. pylori to antibacterial agents such as AMC, CLR, and TET in Moscow, which is consistent with the data of other studies. This negative trend may eventually lead to decreased effectiveness of currently used eradication therapy regimens in Russia.

4 February 2023 in Consilium Medicum
Verified
Journal Article
Open access
YKYury Kucheryavyy
Yury Kucheryavyy
SCSergei V. Cheremushkin
Sergei V. Cheremushkin
КАКучерявый Юрий Александрович
Кучерявый Юрий Александрович
Aim. To compare the therapeutic efficacy of the reference drug ursodoxycholic acid (UDCA) for Russian Federation (Ursofalk) and generic UDCA preparations of other manufacturers in the solution of biliary sludge (BS). Materials and methods. The search for studies was carried out in the electronic databases MEDLINE/PubMed, EMBASE, Cochrane, Russian Science Citation Index (RSCI) until February 2022. Inclusion criteria for the meta-analysis were controlled trials, trials using the reference drug for RF Ursofalk in one of the groups, diagnosis and subsequent assessment of the dynamics of resolution of BS according to transabdominal ultrasound, the absence of simultaneous use of other therapy that could affect therapeutic outcomes, a documented endpoint, which reflects the percentage of the total resolution of the BS in each of the compared groups. Results. The final analysis included 6 studies involving 671 patients with BS (324 with Ursophalc, 347 with other UDCA). When using any UDCA preparations, the generalized frequency of BS dissolution within 3 months was 52.010% (95% confidence interval CI 36.55467.272; I2=94.07%), and after 6 months 78.204% (95% CI 67.84087.024; I2=86.90%). When using the RF reference drug Ursofalk, the generalized frequency of dissolution of BS during 3 months of therapy was 64.826% (95% CI 49.24278.941; I2=87.53%), while when using other UDCA drugs it was 39.187% (95% CI 17.52063.390; I2=95.24%). Ursofalk was more effective than other UDCA preparations (odds ratio OR 3.183; 95% CI 1.495-6.777; I2=74.52%). A similar trend persisted when evaluating the effectiveness of a 6-month course of therapy (OR 4.614; 95% CI 2.8817.388; I2=26.41%). Thus, the generalized frequency of dissolution of BS in the Ursofalk groups was 88.381% (95% CI 80.89094.198; I2=64.98%), and for other UDCA drugs 65.978% (95% CI 60.12571.491; I2=43.22%). Conclusion. This meta-analysis demonstrated that the reference drug UDCA for RF (Ursofalk) is more effective than generic UDCA drugs from other manufacturers in diluting BS.

31 January 2020 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
IMIgor V. Maev
Igor V. Maev
ATA. S. Trukhmanov
A. S. Trukhmanov
ASA. A. Sheptulin
A. A. Sheptulin
VSV. I. Simanenkov
V. I. Simanenkov
SAS. R. Abdulhakov
S. R. Abdulhakov
ГХГ. Я. Хисматуллина
Г. Я. Хисматуллина
Роль нарушений моторики в патогенезе функциональных расстройств желудочнокишечного тракта и современные возможности их лечения (Резолюция Экспертного совета и обзор литературы)

17 October 2025 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
DDD. T. Dicheva
D. T. Dicheva
RBR. M. Brekhunets
R. M. Brekhunets
DADmitrii Nikolaevich Andreev
Dmitrii Nikolaevich Andreev
ELE. G. Lebedeva
E. G. Lebedeva
OBO. E. Berezutskaya
O. E. Berezutskaya
IMIgor V. Maev
Igor V. Maev
Introduction . Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, which affects approximately a quarter of the world's population and has become a global health problem. Aim . To determine the prevalence of NAFLD among patients of Moscow multi-speciality hospitals. Materials and methods . The study was conducted by random screening of patients. In addition to steatosis, the presence of at least two cardiometabolic risks was a necessary criterion for diagnosing NAFLD. All patients underwent abdominal ultrasound imaging and transient elastography (TE) with controlled attenuation parameter (CAP). Hand grip strength (HGS) was measured using a handgrip test. Male patients’ erectile dysfunction (ED) was assessed using the IIEF-5 (International Index of Erectile Function) criteria. Results . A total of 449 patients were examined. Of these, 213 (47.4%) were diagnosed with NAFLD. Among the NAFLD patients, 143 were men and 70 were women. The mean age of the examined patients was 49,3 ± 11,6 years. According to TE findings, mean fibrosis score was 8.9 kPa and mean steatosis score was 294.2 dB/m. Distribution of patients by stages of fibrosis: F0–1 – 75 patients (35.2%), F2 – 69 patients (32.4%), F3 – 47 patients (22.1%), F4 – 22 patients (10.3%). Distribution of patients by stages of liver steatosis: S1 – 70 (32,9%), S2 – 81 (38%), S3 – 62 (29,1%). The mean hand grip strength (HGS) was 33.9 kg, sarcopenia was diagnosed in 30 patients (14.1%). ED was diagnosed in 33 (23.1%) male patients. Distribution of patients by comorbid conditions: impaired glucose tolerance – 74 people (34.7%), type 2 diabetes mellitus – 9 (27.7%), dyslipidemia – 128 (60.1%), high blood pressure – 80 (37.6%), coronary artery disease – 29 (13.6%), gastroesophageal reflux disease – 57 (26.7%), gallbladder disease (cholelithiasis, biliary sludge) – 58 (27.2%), gout – 26 (12.2%), ED (based on IIEF-5 questionnaire scores) – 56 (39.2%). Conclusion . The study has shown that NAFLD is an extremely common disease in multi-speciality hospital settings.

28 August 2025 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
IMIgor V. Maev
Igor V. Maev
DADmitrii Nikolaevich Andreev
Dmitrii Nikolaevich Andreev
RSR I Shaburov
R I Shaburov
AZAndrey Vladimirovich Zaborovsky
Andrey Vladimirovich Zaborovsky
AFAlexey Fomenko
Alexey Fomenko
AVA V Vychkin
A V Vychkin
Aim. To evaluate the efficacy of combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 versus rifaximin monotherapy in patients with small intestinal bacterial overgrowth (SIBO) associated with long-term proton pump inhibitor (PPI) use. Materials and methods. A prospective comparative study with two parallel groups was conducted. Eligible patients were those on continuous long-term PPI therapy ( 3 months) with confirmed SIBO. SIBO was diagnosed in all patients using a lactulose Hydrogen/Methane Breath Test (HMBT). Symptom severity was assessed using the validated "7 × 7" Questionnaire, and Quality of Life (QoL) was evaluated using the SF-36 Health Status Survey. Enrolled patients were randomized into two groups based on a 7-day treatment regimen: Group 1 received rifaximin (400 mg twice daily); Group 2 received rifaximin (400 mg twice daily) plus the probiotic Saccharomyces boulardii CNCM I-745 (Enterol® drug product, Biocodex, France; 500 mg twice daily). SIBO eradication was confirmed via repeat lactulose HMBT, and symptom severity/QoL were reassessed 4 weeks after treatment completion. Results. 108 patients were enrolled (mean age 38.7 ± 8.9 years; 65.7% female). Mean PPI treatment duration at enrollment was 4.81 months (95% confidence interval 4.15–5.46). At 4-week follow-up, repeat lactulose HMBT showed SIBO persistence in 41.5% of Group 1 (n = 22/53) versus 21.8% in Group 2 (n = 12/55; p = 0.038). Statistically significant resolution of diarrhea was observed only in Group 2 (p = 0.033). The final median "7 × 7" Questionnaire score was significantly lower in Group 2 (p = 0.0010). Both groups showed significant trends toward QoL improvement on the SF-36 survey. Conclusion. This prospective comparative study demonstrates that combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 appears more effective than rifaximin monotherapy for SIBO eradication, symptom regression, and QoL improvement in patients with PPI-associated SIBO.

8 October 2021 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
IMIgor V. Maev
Igor V. Maev
AKA. N. Kazyulin
A. N. Kazyulin
YKYury Kucheryavyy
Yury Kucheryavyy
SCS. V. Cheryomushkin
S. V. Cheryomushkin
AGA. Yu. Goncharenko
A. Yu. Goncharenko
ЮКЮ. А. Кучерявый
Ю. А. Кучерявый
Aim. A practical review of functional gastrointestinal disorder diagnosis in constipation patients and the rationale for opting treatment.Key points. Functional constipation commonly afflicts different ages and negatively impacts the quality of life. The current diagnostic algorithm in chronic constipation includes the disease identification according to Rome Criteria IV, red-flag symptom detection and instrumental laboratory examination. Functional constipation is notably often associated with anorectal abnormalities that bear a diagnostic value to elaborate an apt treatment strategy. Anorectal manometry, rectal sensation and balloon expulsion tests are the well-studied and significant probing techniques for objective anorectal zone sensorimotor function assessment in patients with functional constipation. The article reviews modern diagnostic methods in functional defecation disorders.Conclusion. The examination and treatment algorithms presented will help improve diagnosis and apply the most suitable management in a constipation-associated functional digestive pathology.